Method of mapping restriction sites in polynucleotides
CA 2295325 A1 · Owner: Lynx Therapeutics, Inc. · Inventors: Brenner, Sydney
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides a method for constructing a high resolution physical map of a polynucleotide. In accordance with the invention the polynucleotide , is digested successively with at least two different restriction endonucleases and the ends of the restriction fragments are sequenced after each digestion. In this manner, restriction fragments having sequenced ends are produced that can be aligned by their sequences to give a physical map of the polynucleotide. Preferably, restriction fragment ends are sequenced by massively parallel signature sequencing (MPSS) or a like parallel sequencing , technique.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 25, 1998. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 25, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 25, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.